title: BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia.
authors: Xiaoli
authors: X
authors: Wang
authors: Joseph
authors: J
authors: Tripodi
authors: Marina
authors: M
authors: Kremyanskaya
authors: Amanda
authors: A
authors: Blouin
authors: Paul
authors: P
authors: Roda
authors: Ronald
authors: R
authors: Hoffman
authors: Vesna
authors: V
authors: Najfeld
mesh_terms: D019943:Amino Acid Substitution; D003114:Colony-Forming Units Assay; D018450:Disease Progression; D016313:Genes, abl; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006720:Homozygote; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000201:enzymology / Q000209:etiology* / Q000235:genetics* / Q000473:pathology; D020125:Mutation, Missense; D011087:Polycythemia Vera / Q000150:complications* / Q000201:enzymology / Q000235:genetics* / Q000473:pathology
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2